## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($251.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. 2Xideas AG Has $7.33 Million Holdings in Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251209T082531 | Neutral | Relevance: 98%
-  2Xideas AG significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 14.0% in the second quarter, bringing its total holdings to $7.33 million. Despite this, other institutional investors have recently shown increased interest in Labcorp shares, even as some analysts have adjusted price targets and ratings. The medical research company recently reported strong quarterly earnings, beating consensus estimates, and declared a quarterly dividend.

**2. Rep. April McClain Delaney Purchases Shares of Labcorp Holdings Inc. (NYSE:LH)**
- Source: MarketBeat | 20251210T071606 | Somewhat-Bullish | Relevance: 97%
-  Representative April McClain Delaney of Maryland recently purchased shares of Labcorp Holdings Inc. (NYSE:LH) between $1,001 and $15,000 on November 17, 2025. This transaction comes as Labcorp reported strong quarterly earnings, beating EPS estimates and achieving significant revenue growth. The company also declared a quarterly dividend of $0.72 per share, and institutional investors have been actively adjusting their positions in the stock.

**3. Amundi Sells 799,075 Shares of Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251209T120838 | Neutral | Relevance: 97%
-  Amundi significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by selling 799,075 shares, lowering its holdings to 274,307 shares. Despite this large sale, Wall Street maintains a "Moderate Buy" consensus rating for Labcorp with an average target price of $297.07, following a quarter where Labcorp exceeded EPS estimates and announced a quarterly dividend. Insider selling by Director Richelle P. Parham and CEO Adam H. Schechter was also noted.

**4. Gabelli Funds LLC Sells 5,582 Shares of Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251209T094554 | Somewhat-Bullish | Relevance: 97%
-  Gabelli Funds LLC reduced its stake in Labcorp Holdings Inc. ($LH) by 11.2% in the second quarter, selling 5,582 shares and now holding 44,103 shares valued at approximately $11.58 million. Company insiders, including CEO Adam H. Schechter and director Richelle P. Parham, also executed significant share sales. Despite these sales, Labcorp reported strong quarterly results, beating EPS estimates and announcing a quarterly dividend.

**5. Onconetix Amends License Agreement with Labcorp**
- Source: TipRanks | 20251210T145246 | Somewhat-Bullish | Relevance: 74%
-  Onconetix's subsidiary, Proteomedix AG, has amended its license agreement with Labcorp for a new validation study of Proclarix, a prostate cancer risk identification tool. Under the amendment, Labcorp will not pay royalties, and Onconetix will compensate Labcorp up to $300,000 based on milestone achievements. Spark, TipRanksâ€™ AI Analyst, currently rates ONCO as an "Underperform" due to financial difficulties and a bearish technical trend.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Forward P/E 14.9x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.8B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 14.9 |
| Current P/E | 16.0 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.6% to -1.5% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.46% (CS: 33) | Neutral |
| RSI_14 | 47.0 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 0.977x | Below |
| vs SMA200 | 1.018x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $261.99
- **Stop Loss:** $251.19 (4.1% risk)
- **Target:** $272.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 46
- **Position Value:** $12,051.54
- **Portfolio %:** 12.05%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*